Currently, PPARγ is thought to be expressed in the lung and in a murine model of asthma, and treatment with a PPAR-γ agonist can inhibit the development of allergic inflammation, including pulmonary eosinophilia and airway AHR (21). Here, PPARG is linked to asthma.